2,4-Diaminopyrimidine (cas 156-81-0) inhibitors of c-Met kinase bearing benzoxazepine anilines
-
Add time:09/30/2019 Source:infona.pl
Elaboration of the SAR around a series of 2,4-Diaminopyrimidine (cas 156-81-0)s led to a number of c-Met inhibitors in which kinase selectivity was modulated by substituents appended on the C4-aminobenzamide ring and the nature of the C2-aminoaryl ring. Further lead optimization of the C2-aminoaryl group led to benzoxazepine analogs whose pharmaceutical properties were modulated by the nature of the substituent on the benzoxazepine nitrogen. Tumor stasis (with partial regressions) were observed when an orally bioavailable analog was evaluated in a GTL-16 tumor xenograft mouse model. Subsequent PK/PD studies suggested that a metabolite contributed to the overall in vivo response.
We also recommend Trading Suppliers and Manufacturers of 2,4-Diaminopyrimidine (cas 156-81-0). Pls Click Website Link as below: cas 156-81-0 suppliers
Prev:New insights into the structural requirements for pro-apoptotic agents based on 2,4-diaminoquinazoline, 2,4-diaminopyrido[2,3-d]pyrimidine and 2,4-Diaminopyrimidine (cas 156-81-0) derivatives
Next:Comprehensive analysis of the l-arginine/l-Homoarginine (cas 156-86-5)/nitric oxide pathway in preterm neonates: potential roles for Homoarginine (cas 156-86-5) and asymmetric dimethylarginine in foetal growth) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- New insights into the structural requirements for pro-apoptotic agents based on 2,4-diaminoquinazoline, 2,4-diaminopyrido[2,3-d]pyrimidine and 2,4-Diaminopyrimidine (cas 156-81-0) derivatives09/29/2019
- One-pot synthesis and antiproliferative activity of novel 2,4-Diaminopyrimidine (cas 156-81-0) derivatives bearing piperidine and piperazine moieties09/28/2019